Today President Trump promised (again) that he would bring down drug prices and put American patients first. The administration’s approach is to change how Medicare Part B (coverage available as an option for American residents when they are 65 years old or older, or if they qualify through a disability) pays for some of the most expensive prescription drugs, and attempts to imitate (irony alert) what President Trump blames other countries for doing: negotiating prices for their citizens, based largely upon the foreign prices themselves. A planned “international pricing index” (IPI), would cap certain Medicare Part B drug prices to an index from 16 otherRead More →

UACT is disappointed by the preliminary rejection of Yescarta by the UK’s National Institute for Health and Care Excellence (NICE) over its high price, for two reasons: 1) Gilead is asking too much for the treatment which is largely based upon the US National Institutes of Health (NIH owned inventions, and 2) the UK government has not given any public indication it is considering alternatives to withholding coverage to address the problem of an excessive price. Yescarta is the Gilead trade name for axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell (CAR T) technology invented by the NIH, licensed to Kite/Gilead and approved by theRead More →